Treats metastatic non-small cell lung cancer (NSCLC). ANDA 211960, held by Adaptis. Erlotinib Hydrochloride.
As of Nov 22, 2026, ANDA 211960 (Erlotinib Hydrochloride), held by Adaptis, was first approved by FDA on Nov 5, 2019, with 0 approved supplements and 0 published complete response letters.
Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen First-line treatment of patients with locally advanced, unrespectable or metastatic pancreatic cancer, in combination with gemcitabine.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2019 | Original application | Approved | None posted |
| Erlotinib HydrochlorideEQ 25MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
| Erlotinib HydrochlorideEQ 100MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
| Erlotinib HydrochlorideEQ 150MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters